Key result
High miR-185 in DCM linked to ~17% absolute reduction in CV mortality and fewer HF readmissions.
Why the study?
Are high circulating levels of miR-185 associated with improved clinical outcomes and cardiac function in patients with dilated cardiomyopathy?
Cohort (n=91)
No
Are high circulating levels of miR-185 associated with improved clinical outcomes and cardiac function in patients with dilated cardiomyopathy?
Absolute Event Rate: 0% vs 16.7%
p-value: p=0.048
High circulating levels of miR-185 are associated with improved cardiac function, reduced cardiovascular mortality, and fewer heart failure re-hospitalizations in patients with dilated cardiomyopathy.
May support miR-185 for risk stratification in dilated cardiomyopathy; leaves open mechanistic and therapeutic validation.
B cells contribute to the development of dilated cardiomyopathy (DCM) by inducing myocyte injuries and myocardial fibrosis. Our recent research indicated that microRNA (miR) -185 participated in human B-cell activation. Thus, this study was aimed to explore the relationship between miR-185 and DCM progression. Forty-one healthy volunteers and fifty newly diagnosed DCM patients were enrolled. The levels of plasma miR-185, TNF-α secreting B cells, and anti-heart autoantibody were detected. We found that the mean levels of plasma miR-185 in DCM patients were significantly higher than those in healthy controls. Furthermore, these DCM patients could be divided into miR-185(high) and miR-185(low) groups according to the cluster distribution. During one-year follow-up period, the miR-185(high) group showed apparent improvements in left ventricular ejection fraction, left ventricular end diastolic diameter, and NT-proBNP, accompanied by significant declines in both cardiovascular mortality and total admissions for heart failure re-hospitalizations. In addition, the levels of anti-β1-AR antibody and TNF-α secreting B cells were also reduced in miR-185(high) group. These findings suggested that high miR-185 levels might be associated with a favorable prognosis by repressing B cell function in DCM. The findings of this study need to be confirmed with larger sample size and longer duration of observation.
No takes yet. Share an insight, caveat, or question.
Yu et al. (2016) conducted a cohort in Dilated cardiomyopathy (n=91). High circulating miR-185 levels vs. Low circulating miR-185 levels was evaluated on Cardiovascular mortality at 12 months (p=0.048). High circulating miR-185 levels in patients with dilated cardiomyopathy were associated with significantly lower cardiovascular mortality (0% vs 16.7%) and fewer heart failure re-hospitalizations compared to low miR-185 levels over a 1-year follow-up.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: